English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 904962      Online Users : 748
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/9961


    Title: Chinese herbal mixture, tien-hsien liquid, induces G2/M cycle arrest and radiosensitivity in MCF-7 human breast cancer cells through mechanisms involving DNMT1 and Rad51 downregulation
    Authors: Yao, CJ;Chow, JM;Yang, CM;Kuo, HC;Chang, CL;Lee, HL;Lai, IC;Chuang, SE;Lai, GM
    Contributors: National Institute of Cancer Research
    Abstract: The Chinese herbal mixture, Tien-Hsien Liquid (THL), has been proven to suppress the growth and invasiveness of cancer cells and is currently regarded as a complementary medicine for the treatment of cancer. Our previous study using acute promyelocytic leukemia cells uncovered its effect on the downregulation of DNA methyltransferase 1 (DNMT1) which is often overexpressed in cancer cells resulting in the repression of tumor suppressors via hypermethylation. Herein, we explored the effects of THL in MCF-7 breast cancer cells that also demonstrate elevated DNMT1. The results show that THL dose-dependently downregulated DNMT1 accompanied by the induction of tumor suppressors such as p21 and p15. THL arrested cell cycle in G2/M phase and decreased the protein levels of cyclin A, cyclin B1, phospho-pRb, and AKT. DNMT1 inhibition was previously reported to exert a radiosensitizing effect in cancer cells through the repression of DNA repair. We found that THL enhanced radiation-induced clonogenic cell death in MCF-7 cells and decreased the level of DNA double-strand break repair protein, Rad51. Our observations may be the result of DNMT1 downregulation. Due to the fact that DNMT1 inhibition is now a mainstream strategy for anticancer therapy, further clinical trials of THL to confirm its clinical efficacy are warranted.
    Date: 2016-08
    Relation: Evidence-Based Complementary and Alternative Medicine. 2016 Aug;2016:Article number 3251046.
    Link to: http://dx.doi.org/10.1155/2016/3251046
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000380704700001
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84982813093
    Appears in Collections:[賴基銘(2004-2008)] 期刊論文
    [莊雙恩] 期刊論文

    Files in This Item:

    File Description SizeFormat
    SCP84980707880.pdf3788KbAdobe PDF527View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback